These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12860164)

  • 1. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.
    Hadden J; Verastegui E; Barrera JL; Kurman M; Meneses A; Zinser JW; de la Garza J; Hadden E
    Int Immunopharmacol; 2003 Aug; 3(8):1073-81. PubMed ID: 12860164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
    Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
    Meneses A; Verastegui E; Barrera JL; Zinser J; de la Garza J; Hadden JW
    Arch Pathol Lab Med; 1998 May; 122(5):447-54. PubMed ID: 9593347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
    Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
    Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
    Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
    J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
    Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
    Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
    Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
    Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
    Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K
    Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E
    J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
    Freeman SM; Franco JL; Kenady DE; Baltzer L; Roth Z; Brandwein HJ; Hadden JW
    Am J Clin Oncol; 2011 Apr; 34(2):173-8. PubMed ID: 20539208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
    Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.